Azole antifungals: Difference between revisions

From Doc Moates Wiki
Jump to navigation Jump to search
NCLEX nursing pharmacology monographs — batch import
 
Add medication infobox (Drugbox) to monographs
 
Line 1: Line 1:
{{Drugbox
| name = Azole antifungals
| therapeutic = Antifungal
| pharmacologic = Azole (ergosterol synthesis inhibitor)
| onset = Fluconazole once daily with good oral absorption.
| halflife = Fluconazole about 30 hours; voriconazole levels sometimes monitored.
| routes = PO (oral), IV
| highalert = No
| blackbox = <span style="color:#b00020;">'''Yes'''</span> (see Safety)
| antidote = Supportive care.
| pregnancy = High-dose fluconazole avoided in pregnancy.
}}
<div style="border-left:4px solid #3f6f5b;background:#f3f6f4;padding:8px 12px;margin-bottom:12px;font-size:0.95em;">
<div style="border-left:4px solid #3f6f5b;background:#f3f6f4;padding:8px 12px;margin-bottom:12px;font-size:0.95em;">
''Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and '''must be verified against current manufacturer labeling before clinical use'''. This is educational content, not prescribing guidance.''
''Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and '''must be verified against current manufacturer labeling before clinical use'''. This is educational content, not prescribing guidance.''

Latest revision as of 16:09, 17 June 2026

Azole antifungals
Drug monograph · NCLEX study reference
Therapeutic classAntifungal
Pharmacologic classAzole (ergosterol synthesis inhibitor)
Onset / peak / durationFluconazole once daily with good oral absorption.
Half-life / levelFluconazole about 30 hours; voriconazole levels sometimes monitored.
RoutesPO (oral), IV
High-alert (ISMP)No
Black box warningYes (see Safety)
Antidote / reversalSupportive care.
Pregnancy / lactationHigh-dose fluconazole avoided in pregnancy.

Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.

Azole antifungals — Antifungal; Azole (ergosterol synthesis inhibitor).

Identification

  • Therapeutic class: Antifungal.
  • Pharmacologic class: Azole (ergosterol synthesis inhibitor).

Pharmacology

  • Mechanism of action: Inhibit fungal cell membrane sterol synthesis.
  • Onset / peak / duration: Fluconazole once daily with good oral absorption.
  • Half-life / therapeutic level: Fluconazole about 30 hours; voriconazole levels sometimes monitored.

Clinical use

  • Indications: Candidiasis (oral, esophageal, vaginal, systemic), cryptococcal meningitis, aspergillosis (voriconazole), various systemic fungal infections.
  • Usual dose, route, frequency: Fluconazole PO or IV daily; others by infection.
  • Maximum dose / adjustments: Reduce fluconazole in renal impairment; voriconazole and itraconazole adjusted by hepatic function.

Safety

  • Contraindications: Coadministration with many QT-prolonging and CYP3A4-dependent drugs; ketoconazole and itraconazole in heart failure.
  • Black box warning: Oral ketoconazole carries a boxed warning for hepatotoxicity and serious QT-related drug interactions (reserved use); itraconazole carries a boxed warning for negative inotropic effects and heart failure and serious interactions.
  • Interactions: Strong CYP inhibition raises levels of warfarin, statins, many drugs; QT-prolonging drugs; antacids and acid reducers lower ketoconazole and itraconazole absorption.
  • Pregnancy / lactation: High-dose fluconazole avoided in pregnancy.
  • High-alert: No.

Adverse effects

  • Common side effects: Nausea, headache, rash; voriconazole causes visual disturbances.
  • Serious effects to report: Hepatotoxicity, QT prolongation, severe rash, heart failure (itraconazole).
  • Antidote / reversal: Supportive care.

Nursing process

  • Assessment before administration: LFTs, cardiac and QT history, interacting drugs.
  • Interventions during therapy: Review interacting drugs carefully; monitor liver function.
  • Monitor: LFTs, ECG if at risk, infection resolution, vision (voriconazole).
  • Evaluation / expected outcome: Resolution of fungal infection.

Patient teaching

  • Patient teaching: Report yellowing of skin; voriconazole may cause temporary vision changes and sun sensitivity.
  • Notify provider if: Yellowing of skin, dark urine, palpitations, vision changes.
  • Administration tips: Many interactions; verify before adding other drugs.